Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 301 entries
Sorted by: Best Match Show Resources per page
A FZD7-specific Antibody-Drug Conjugate Induces Ovarian Tumor Regression in Preclinical Models.

Molecular cancer therapeutics

Do M, Wu CCN, Sonavane PR, Juarez EF, Adams SR, Ross J, Rodriguez Y Baena A, Patel C, Mesirov JP, Carson DA, Advani SJ, Willert K.
PMID: 34667113
Mol Cancer Ther. 2022 Jan;21(1):113-124. doi: 10.1158/1535-7163.MCT-21-0548. Epub 2021 Oct 19.

Although WNT signaling is frequently dysregulated in solid tumors, drugging this pathway has been challenging due to off-tumor effects. Current clinical pan-WNT inhibitors are nonspecific and lead to adverse effects, highlighting the urgent need for more specific WNT pathway-targeting...

Cite
Do M, Wu CCN, Sonavane PR, et al. A FZD7-specific Antibody-Drug Conjugate Induces Ovarian Tumor Regression in Preclinical Models. Mol Cancer Ther. 2021;21(1):113-124doi: 10.1158/1535-7163.MCT-21-0548.
Do, M., Wu, C. C. N., Sonavane, P. R., Juarez, E. F., Adams, S. R., Ross, J., Rodriguez Y Baena, A., Patel, C., Mesirov, J. P., Carson, D. A., Advani, S. J., & Willert, K. (2022). A FZD7-specific Antibody-Drug Conjugate Induces Ovarian Tumor Regression in Preclinical Models. Molecular cancer therapeutics, 21(1), 113-124. https://doi.org/10.1158/1535-7163.MCT-21-0548
Do, Myan, et al. "A FZD7-specific Antibody-Drug Conjugate Induces Ovarian Tumor Regression in Preclinical Models." Molecular cancer therapeutics vol. 21,1 (2022): 113-124. doi: https://doi.org/10.1158/1535-7163.MCT-21-0548
Do M, Wu CCN, Sonavane PR, Juarez EF, Adams SR, Ross J, Rodriguez Y Baena A, Patel C, Mesirov JP, Carson DA, Advani SJ, Willert K. A FZD7-specific Antibody-Drug Conjugate Induces Ovarian Tumor Regression in Preclinical Models. Mol Cancer Ther. 2022 Jan;21(1):113-124. doi: 10.1158/1535-7163.MCT-21-0548. Epub 2021 Oct 19. PMID: 34667113.
Copy Download .nbib Format: NLM
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021.

Journal of the National Comprehensive Cancer Network : JNCCN

Zelenetz AD, Gordon LI, Chang JE, Christian B, Abramson JS, Advani RH, Bartlett NL, Budde LE, Caimi PF, De Vos S, Dholaria B, Fakhri B, Fayad LE, Glenn MJ, Habermann TM, Hernandez-Ilizaliturri F, Hsi E, Hu B, Kaminski MS, Kelsey CR, Khan N, Krivacic S, LaCasce AS, Lim M, Narkhede M, Rabinovitch R, Ramakrishnan P, Reid E, Roberts KB, Saeed H, Smith SD, Svoboda J, Swinnen LJ, Tuscano J, Vose JM, Dwyer MA, Sundar H.
PMID: 34781267
J Natl Compr Canc Netw. 2021 Nov;19(11):1218-1230. doi: 10.6004/jnccn.2021.0054.

In the last decade, a better understanding of the molecular pathogenesis of B-cell non-Hodgkin lymphomas has resulted in the development of novel targeted therapies, such as small molecule inhibitors of select kinases in the B-cell receptor pathway, antibody-drug conjugates,...

Cite
Zelenetz AD, Gordon LI, Chang JE, et al. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021. J Natl Compr Canc Netw. 2021;19(11):1218-1230doi: 10.6004/jnccn.2021.0054.
Zelenetz, A. D., Gordon, L. I., Chang, J. E., Christian, B., Abramson, J. S., Advani, R. H., Bartlett, N. L., Budde, L. E., Caimi, P. F., De Vos, S., Dholaria, B., Fakhri, B., Fayad, L. E., Glenn, M. J., Habermann, T. M., Hernandez-Ilizaliturri, F., Hsi, E., Hu, B., Kaminski, M. S., Kelsey, C. R., Khan, N., Krivacic, S., LaCasce, A. S., Lim, M., Narkhede, M., Rabinovitch, R., Ramakrishnan, P., Reid, E., Roberts, K. B., Saeed, H., Smith, S. D., Svoboda, J., Swinnen, L. J., Tuscano, J., Vose, J. M., Dwyer, M. A., & Sundar, H. (2021). NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021. Journal of the National Comprehensive Cancer Network : JNCCN, 19(11), 1218-1230. https://doi.org/10.6004/jnccn.2021.0054
Zelenetz, Andrew D, et al. "NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021." Journal of the National Comprehensive Cancer Network : JNCCN vol. 19,11 (2021): 1218-1230. doi: https://doi.org/10.6004/jnccn.2021.0054
Zelenetz AD, Gordon LI, Chang JE, Christian B, Abramson JS, Advani RH, Bartlett NL, Budde LE, Caimi PF, De Vos S, Dholaria B, Fakhri B, Fayad LE, Glenn MJ, Habermann TM, Hernandez-Ilizaliturri F, Hsi E, Hu B, Kaminski MS, Kelsey CR, Khan N, Krivacic S, LaCasce AS, Lim M, Narkhede M, Rabinovitch R, Ramakrishnan P, Reid E, Roberts KB, Saeed H, Smith SD, Svoboda J, Swinnen LJ, Tuscano J, Vose JM, Dwyer MA, Sundar H. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021. J Natl Compr Canc Netw. 2021 Nov;19(11):1218-1230. doi: 10.6004/jnccn.2021.0054. PMID: 34781267.
Copy Download .nbib Format: NLM
G3BP2-KIT drives leukemia amenable to kinase inhibition in Ph-like ALL.

Blood advances

Iacobucci I, Fukano R, Friske J, Qu C, Janke LJ, Zhao Y, Baviskar P, Backhaus E, Chockley P, Seth A, Laird AD, Advani AS, Mullighan CG.
PMID: 34991158
Blood Adv. 2022 Jan 06; doi: 10.1182/bloodadvances.2021004854. Epub 2022 Jan 06.

No abstract available.

Cite
Iacobucci I, Fukano R, Friske J, et al. G3BP2-KIT drives leukemia amenable to kinase inhibition in Ph-like ALL. Blood Adv. 2022;doi: 10.1182/bloodadvances.2021004854.
Iacobucci, I., Fukano, R., Friske, J., Qu, C., Janke, L. J., Zhao, Y., Baviskar, P., Backhaus, E., Chockley, P., Seth, A., Laird, A. D., Advani, A. S., & Mullighan, C. G. (2022). G3BP2-KIT drives leukemia amenable to kinase inhibition in Ph-like ALL. Blood advances, . https://doi.org/10.1182/bloodadvances.2021004854
Iacobucci, Ilaria, et al. "G3BP2-KIT drives leukemia amenable to kinase inhibition in Ph-like ALL." Blood advances vol. (2022). doi: https://doi.org/10.1182/bloodadvances.2021004854
Iacobucci I, Fukano R, Friske J, Qu C, Janke LJ, Zhao Y, Baviskar P, Backhaus E, Chockley P, Seth A, Laird AD, Advani AS, Mullighan CG. G3BP2-KIT drives leukemia amenable to kinase inhibition in Ph-like ALL. Blood Adv. 2022 Jan 06; doi: 10.1182/bloodadvances.2021004854. Epub 2022 Jan 06. PMID: 34991158.
Copy Download .nbib Format: NLM
Thigh and Leg Muscle MRI Findings in GNE Myopathy.

Journal of neuromuscular diseases

Fatehi F, Advani S, Okhovat AA, Ziaadini B, Shamshiri H, Nafissi S.
PMID: 34334416
J Neuromuscul Dis. 2021;8(4):735-742. doi: 10.3233/JND-210629.

BACKGROUND: Muscle MRI protocols have been developed to assess muscle involvement in a wide variety of muscular dystrophies. Different muscular dystrophies can involve muscle groups in characteristic patterns. These patterns can be identified in muscle MRI in the form...

Cite
Fatehi F, Advani S, Okhovat AA, et al. Thigh and Leg Muscle MRI Findings in GNE Myopathy. J Neuromuscul Dis. 2021;8(4):735-742doi: 10.3233/JND-210629.
Fatehi, F., Advani, S., Okhovat, A. A., Ziaadini, B., Shamshiri, H., & Nafissi, S. (2021). Thigh and Leg Muscle MRI Findings in GNE Myopathy. Journal of neuromuscular diseases, 8(4), 735-742. https://doi.org/10.3233/JND-210629
Fatehi, Farzad, et al. "Thigh and Leg Muscle MRI Findings in GNE Myopathy." Journal of neuromuscular diseases vol. 8,4 (2021): 735-742. doi: https://doi.org/10.3233/JND-210629
Fatehi F, Advani S, Okhovat AA, Ziaadini B, Shamshiri H, Nafissi S. Thigh and Leg Muscle MRI Findings in GNE Myopathy. J Neuromuscul Dis. 2021;8(4):735-742. doi: 10.3233/JND-210629. PMID: 34334416.
Copy Download .nbib Format: NLM
Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic.

HemaSphere

Talaulikar D, Advani RH, Branagan AR, Buske C, Dimopoulos MA, D'Sa S, Kersten MJ, Leblond V, Minnema MC, Owen RG, Palomba ML, Tedeschi A, Trotman J, Varettoni M, Vos JM, Treon SP, Kastritis E, Castillo JJ.
PMID: 32803133
Hemasphere. 2020 Jul 30;4(4):e433. doi: 10.1097/HS9.0000000000000433. eCollection 2020 Aug.

In the light of the COVID-19 pandemic, the International Workshop on Waldenström Macroglobulinemia (IWWM) Treatment Recommendations Panel felt the need to provide a consensus statement for the management of Waldenström Macroglobulinemia (WM) patients during this challenging time. We followed...

Cite
Talaulikar D, Advani RH, Branagan AR, et al. Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic. Hemasphere. 2020;4(4):e433doi: 10.1097/HS9.0000000000000433.
Talaulikar, D., Advani, R. H., Branagan, A. R., Buske, C., Dimopoulos, M. A., D'Sa, S., Kersten, M. J., Leblond, V., Minnema, M. C., Owen, R. G., Palomba, M. L., Tedeschi, A., Trotman, J., Varettoni, M., Vos, J. M., Treon, S. P., Kastritis, E., & Castillo, J. J. (2020). Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic. HemaSphere, 4(4), e433. https://doi.org/10.1097/HS9.0000000000000433
Talaulikar, Dipti, et al. "Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic." HemaSphere vol. 4,4 (2020): e433. doi: https://doi.org/10.1097/HS9.0000000000000433
Talaulikar D, Advani RH, Branagan AR, Buske C, Dimopoulos MA, D'Sa S, Kersten MJ, Leblond V, Minnema MC, Owen RG, Palomba ML, Tedeschi A, Trotman J, Varettoni M, Vos JM, Treon SP, Kastritis E, Castillo JJ. Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic. Hemasphere. 2020 Jul 30;4(4):e433. doi: 10.1097/HS9.0000000000000433. eCollection 2020 Aug. PMID: 32803133; PMCID: PMC7410025.
Copy Download .nbib Format: NLM
Learning the Macroscopic Flow Model of Short Fiber Suspensions from Fine-Scale Simulated Data.

Entropy (Basel, Switzerland)

Yun M, Argerich Martin C, Giormini P, Chinesta F, Advani S.
PMID: 33285805
Entropy (Basel). 2019 Dec 24;22(1). doi: 10.3390/e22010030.

Fiber-fiber interaction plays an important role in the evolution of fiber orientation in semi-concentrated suspensions. Flow induced orientation in short-fiber reinforced composites determines the anisotropic properties of manufactured parts and consequently their performances. In the case of dilute suspensions,...

Cite
Yun M, Argerich Martin C, Giormini P, et al. Learning the Macroscopic Flow Model of Short Fiber Suspensions from Fine-Scale Simulated Data. Entropy (Basel). 2019;22(1)doi: 10.3390/e22010030.
Yun, M., Argerich Martin, C., Giormini, P., Chinesta, F., & Advani, S. (2019). Learning the Macroscopic Flow Model of Short Fiber Suspensions from Fine-Scale Simulated Data. Entropy (Basel, Switzerland), 22(1), . https://doi.org/10.3390/e22010030
Yun, Minyoung, et al. "Learning the Macroscopic Flow Model of Short Fiber Suspensions from Fine-Scale Simulated Data." Entropy (Basel, Switzerland) vol. 22,1 (2019). doi: https://doi.org/10.3390/e22010030
Yun M, Argerich Martin C, Giormini P, Chinesta F, Advani S. Learning the Macroscopic Flow Model of Short Fiber Suspensions from Fine-Scale Simulated Data. Entropy (Basel). 2019 Dec 24;22(1). doi: 10.3390/e22010030. PMID: 33285805; PMCID: PMC7516452.
Copy Download .nbib Format: NLM
Mammography adherence in relation to function-related indicators in older women.

Preventive medicine

Zhang D, Abraham L, Sprague BL, Onega T, Advani S, Demb J, Miglioretti DL, Henderson LM, Wernli KJ, Walter LC, Kerlikowske K, Schousboe JT, Chrischilles E, Braithwaite D, O'Meara ES.
PMID: 34762965
Prev Med. 2021 Nov 09;154:106869. doi: 10.1016/j.ypmed.2021.106869. Epub 2021 Nov 09.

Prior studies of screening mammography patterns by functional status in older women show inconsistent results. We used Breast Cancer Surveillance Consortium-Medicare linked data (1999-2014) to investigate the association of functional limitations with adherence to screening mammography in 145,478 women...

Cite
Zhang D, Abraham L, Sprague BL, et al. Mammography adherence in relation to function-related indicators in older women. Prev Med. 2021;154:106869doi: 10.1016/j.ypmed.2021.106869.
Zhang, D., Abraham, L., Sprague, B. L., Onega, T., Advani, S., Demb, J., Miglioretti, D. L., Henderson, L. M., Wernli, K. J., Walter, L. C., Kerlikowske, K., Schousboe, J. T., Chrischilles, E., Braithwaite, D., O'Meara, E. S. (2021). Mammography adherence in relation to function-related indicators in older women. Preventive medicine, 154106869. https://doi.org/10.1016/j.ypmed.2021.106869
Zhang, Dongyu, et al. "Mammography adherence in relation to function-related indicators in older women." Preventive medicine vol. 154 (2021): 106869. doi: https://doi.org/10.1016/j.ypmed.2021.106869
Zhang D, Abraham L, Sprague BL, Onega T, Advani S, Demb J, Miglioretti DL, Henderson LM, Wernli KJ, Walter LC, Kerlikowske K, Schousboe JT, Chrischilles E, Braithwaite D, O'Meara ES. Mammography adherence in relation to function-related indicators in older women. Prev Med. 2021 Nov 09;154:106869. doi: 10.1016/j.ypmed.2021.106869. Epub 2021 Nov 09. PMID: 34762965.
Copy Download .nbib Format: NLM
Epidemiology and Molecular-Pathologic Characteristics of CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer.

Clinical colorectal cancer

Advani SM, Swartz MD, Loree J, Davis JS, Sarsashek AM, Lam M, Lee MS, Bressler J, Lopez DS, Daniel CR, Morris V, Shureqi I, Kee B, Dasari A, Vilar E, Overman M, Hamilton S, Maru D, Braithwaite D, Kopetz S.
PMID: 33229221
Clin Colorectal Cancer. 2021 Jun;20(2):137-147.e1. doi: 10.1016/j.clcc.2020.09.007. Epub 2020 Oct 12.

BACKGROUND: CpG island methylator phenotype (CIMP) forms a distinct epigenetic phenotype in colorectal cancer (CRC). Though associated with distinct clinicopathologic characteristics, limited evidence exists of the association of CIMP with patient's reported lifestyle factors and tumor molecular characteristics. We...

Cite
Advani SM, Swartz MD, Loree J, et al. Epidemiology and Molecular-Pathologic Characteristics of CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer. Clin Colorectal Cancer. 2020;20(2):137-147.e1doi: 10.1016/j.clcc.2020.09.007.
Advani, S. M., Swartz, M. D., Loree, J., Davis, J. S., Sarsashek, A. M., Lam, M., Lee, M. S., Bressler, J., Lopez, D. S., Daniel, C. R., Morris, V., Shureqi, I., Kee, B., Dasari, A., Vilar, E., Overman, M., Hamilton, S., Maru, D., Braithwaite, D., & Kopetz, S. (2021). Epidemiology and Molecular-Pathologic Characteristics of CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer. Clinical colorectal cancer, 20(2), 137-147.e1. https://doi.org/10.1016/j.clcc.2020.09.007
Advani, Shailesh M, et al. "Epidemiology and Molecular-Pathologic Characteristics of CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer." Clinical colorectal cancer vol. 20,2 (2021): 137-147.e1. doi: https://doi.org/10.1016/j.clcc.2020.09.007
Advani SM, Swartz MD, Loree J, Davis JS, Sarsashek AM, Lam M, Lee MS, Bressler J, Lopez DS, Daniel CR, Morris V, Shureqi I, Kee B, Dasari A, Vilar E, Overman M, Hamilton S, Maru D, Braithwaite D, Kopetz S. Epidemiology and Molecular-Pathologic Characteristics of CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer. Clin Colorectal Cancer. 2021 Jun;20(2):137-147.e1. doi: 10.1016/j.clcc.2020.09.007. Epub 2020 Oct 12. PMID: 33229221.
Copy Download .nbib Format: NLM
One hundred years since insulin discovery: An update on current and future perspectives for pharmacotherapy of diabetes mellitus.

British journal of clinical pharmacology

Seetharaman R, Pawar S, Advani M.
PMID: 34608666
Br J Clin Pharmacol. 2021 Oct 04; doi: 10.1111/bcp.15100. Epub 2021 Oct 04.

Diabetes mellitus was considered a fatal malady until the discovery, extraction and commercial availability of insulins. Numerous other classes of drugs ranging from sulfonylureas to sodium-glucose co-transporter-2 inhibitors were then marketed. However, with the prevalence of diabetes mellitus increasing...

Cite
Seetharaman R, Pawar S, Advani M. One hundred years since insulin discovery: An update on current and future perspectives for pharmacotherapy of diabetes mellitus. Br J Clin Pharmacol. 2021;doi: 10.1111/bcp.15100.
Seetharaman, R., Pawar, S., & Advani, M. (2021). One hundred years since insulin discovery: An update on current and future perspectives for pharmacotherapy of diabetes mellitus. British journal of clinical pharmacology, . https://doi.org/10.1111/bcp.15100
Seetharaman, Rajmohan, et al. "One hundred years since insulin discovery: An update on current and future perspectives for pharmacotherapy of diabetes mellitus." British journal of clinical pharmacology vol. (2021). doi: https://doi.org/10.1111/bcp.15100
Seetharaman R, Pawar S, Advani M. One hundred years since insulin discovery: An update on current and future perspectives for pharmacotherapy of diabetes mellitus. Br J Clin Pharmacol. 2021 Oct 04; doi: 10.1111/bcp.15100. Epub 2021 Oct 04. PMID: 34608666.
Copy Download .nbib Format: NLM
Cost-Effectiveness of Screening Mammography Beyond Age 75 Years : A Cost-Effectiveness Analysis.

Annals of internal medicine

Schousboe JT, Sprague BL, Abraham L, O'Meara ES, Onega T, Advani S, Henderson LM, Wernli KJ, Zhang D, Miglioretti DL, Braithwaite D, Kerlikowske K.
PMID: 34807717
Ann Intern Med. 2022 Jan;175(1):11-19. doi: 10.7326/M20-8076. Epub 2021 Nov 23.

BACKGROUND: The cost-effectiveness of screening mammography beyond age 75 years remains unclear.OBJECTIVE: To estimate benefits, harms, and cost-effectiveness of extending mammography to age 80, 85, or 90 years according to comorbidity burden.DESIGN: Markov microsimulation model.DATA SOURCES: SEER (Surveillance, Epidemiology,...

Cite
Schousboe JT, Sprague BL, Abraham L, et al. Cost-Effectiveness of Screening Mammography Beyond Age 75 Years : A Cost-Effectiveness Analysis. Ann Intern Med. 2021;175(1):11-19doi: 10.7326/M20-8076.
Schousboe, J. T., Sprague, B. L., Abraham, L., O'Meara, E. S., Onega, T., Advani, S., Henderson, L. M., Wernli, K. J., Zhang, D., Miglioretti, D. L., Braithwaite, D., & Kerlikowske, K. (2022). Cost-Effectiveness of Screening Mammography Beyond Age 75 Years : A Cost-Effectiveness Analysis. Annals of internal medicine, 175(1), 11-19. https://doi.org/10.7326/M20-8076
Schousboe, John T, et al. "Cost-Effectiveness of Screening Mammography Beyond Age 75 Years : A Cost-Effectiveness Analysis." Annals of internal medicine vol. 175,1 (2022): 11-19. doi: https://doi.org/10.7326/M20-8076
Schousboe JT, Sprague BL, Abraham L, O'Meara ES, Onega T, Advani S, Henderson LM, Wernli KJ, Zhang D, Miglioretti DL, Braithwaite D, Kerlikowske K. Cost-Effectiveness of Screening Mammography Beyond Age 75 Years : A Cost-Effectiveness Analysis. Ann Intern Med. 2022 Jan;175(1):11-19. doi: 10.7326/M20-8076. Epub 2021 Nov 23. PMID: 34807717.
Copy Download .nbib Format: NLM
Sustained reduction in catheter-associated urinary tract infections using multi-faceted strategies led by champions: A quality improvement initiative.

Infection control and hospital epidemiology

Reynolds SS, Sova CD, Lewis SS, Smith BA, Wrenn RH, Turner NA, Advani SD.
PMID: 33858549
Infect Control Hosp Epidemiol. 2021 Apr 16;1-5. doi: 10.1017/ice.2021.135. Epub 2021 Apr 16.

We reviewed the sustainability of a multifaceted intervention on catheter-associated urinary tract infection (CAUTI) in 3 intensive care units. During the 4-year postintervention period, we observed reductions in urine culture rates (from 80.9 to 47.5 per 1,000 patient days;...

Cite
Reynolds SS, Sova CD, Lewis SS, et al. Sustained reduction in catheter-associated urinary tract infections using multi-faceted strategies led by champions: A quality improvement initiative. Infect Control Hosp Epidemiol. 2021;1-5doi: 10.1017/ice.2021.135.
Reynolds, S. S., Sova, C. D., Lewis, S. S., Smith, B. A., Wrenn, R. H., Turner, N. A., & Advani, S. D. (2021). Sustained reduction in catheter-associated urinary tract infections using multi-faceted strategies led by champions: A quality improvement initiative. Infection control and hospital epidemiology, 1-5. https://doi.org/10.1017/ice.2021.135
Reynolds, Staci S, et al. "Sustained reduction in catheter-associated urinary tract infections using multi-faceted strategies led by champions: A quality improvement initiative." Infection control and hospital epidemiology vol. (2021): 1-5. doi: https://doi.org/10.1017/ice.2021.135
Reynolds SS, Sova CD, Lewis SS, Smith BA, Wrenn RH, Turner NA, Advani SD. Sustained reduction in catheter-associated urinary tract infections using multi-faceted strategies led by champions: A quality improvement initiative. Infect Control Hosp Epidemiol. 2021 Apr 16;1-5. doi: 10.1017/ice.2021.135. Epub 2021 Apr 16. PMID: 33858549; PMCID: PMC8521571.
Copy Download .nbib Format: NLM
Association of Breast Density With Breast Cancer Risk Among Women Aged 65 Years or Older by Age Group and Body Mass Index.

JAMA network open

Advani SM, Zhu W, Demb J, Sprague BL, Onega T, Henderson LM, Buist DSM, Zhang D, Schousboe JT, Walter LC, Kerlikowske K, Miglioretti DL, Braithwaite D.
PMID: 34436608
JAMA Netw Open. 2021 Aug 02;4(8):e2122810. doi: 10.1001/jamanetworkopen.2021.22810.

IMPORTANCE: Breast density is associated with breast cancer risk in women aged 40 to 65 years, but there is limited evidence of its association with risk of breast cancer among women aged 65 years or older.OBJECTIVE: To compare the...

Cite
Advani SM, Zhu W, Demb J, et al. Association of Breast Density With Breast Cancer Risk Among Women Aged 65 Years or Older by Age Group and Body Mass Index. JAMA Netw Open. 2021;4(8):e2122810doi: 10.1001/jamanetworkopen.2021.22810.
Advani, S. M., Zhu, W., Demb, J., Sprague, B. L., Onega, T., Henderson, L. M., Buist, D. S. M., Zhang, D., Schousboe, J. T., Walter, L. C., Kerlikowske, K., Miglioretti, D. L., Braithwaite, D. (2021). Association of Breast Density With Breast Cancer Risk Among Women Aged 65 Years or Older by Age Group and Body Mass Index. JAMA network open, 4(8), e2122810. https://doi.org/10.1001/jamanetworkopen.2021.22810
Advani, Shailesh M, et al. "Association of Breast Density With Breast Cancer Risk Among Women Aged 65 Years or Older by Age Group and Body Mass Index." JAMA network open vol. 4,8 (2021): e2122810. doi: https://doi.org/10.1001/jamanetworkopen.2021.22810
Advani SM, Zhu W, Demb J, Sprague BL, Onega T, Henderson LM, Buist DSM, Zhang D, Schousboe JT, Walter LC, Kerlikowske K, Miglioretti DL, Braithwaite D. Association of Breast Density With Breast Cancer Risk Among Women Aged 65 Years or Older by Age Group and Body Mass Index. JAMA Netw Open. 2021 Aug 02;4(8):e2122810. doi: 10.1001/jamanetworkopen.2021.22810. PMID: 34436608; PMCID: PMC8391100.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 301 entries